Table 2.
Baseline Symptoms and Virology of Participants With Influenza Confirmed in Central Laboratory Testing
| Symptoms and Virology | Total | Oseltamivir | Placebo |
|---|---|---|---|
| (N =; 501) | (n =; 246) | (n =; 255) | |
| Overall symptom score (11 symptoms, graded 0–3) | |||
| Median (quartiles) | 13 (10, 17) | 13 (10, 17) | 13 (10, 17) |
| Min, Max | 3, 27 | 3, 27 | 3, 27 |
| Average functional status (physical domain of the SF-36) | |||
| Prior to illness–median (Q1:Q3) | 100 (95, 100) | 100 (90, 100) | 100 (95, 100) |
| Day 0–median (Q1:Q3) | 65 (40, 75) | 65 (40, 75) | 65 (35, 75) |
| Global assessment | |||
| Participant feels as good today as before illness (no) | 531 (97%) | 260 (95%) | 271 (98%) |
| Participant functions as well today as before illness (no) | 461 (84%) | 224 (82%) | 237 (86%) |
| Complications at baseline | |||
| Sinusitis | 7 (1%) | 4 (1%) | 3 (1%) |
| Otitis media | 1 (<0.5%) | 0 (0%) | 1 (<0.5%) |
| Bronchitis/Bronchiolitis | 6 (1%) | 4 (1%) | 2 (1%) |
| Pneumonia | 1 (<0.5%) | 0 (0%) | 1 (<0.5%) |
| Using antibiotic for other reasons | 11 (2%) | 6 (2%) | 5 (2%) |
| Virology | |||
| Mean (standard deviation) log10 copies/mL | 6.6 (1.3) | 6.6 (1.3) | 6.6 (1.3) |
| Median (quartiles) log10 copies/mL | 6.9 (5.8, 7.6) | 6.9 (5.8, 7.6) | 6.9 (5.9, 7.6) |
| Detection on quantitative assay | |||
| ≥LLOQ | 482 (96%) | 237 (96%) | 245 (96%) |
| ≥LOD, <LLOQ | 11 (2%) | 6 (2%) | 5 (2%) |
| <LOD | 8 (2%) | 3 (1%) | 5 (2%) |
| Presence of glyceraldehyde-3-phosphate dehydrogenase | |||
| ≥LOD/LLOQ, =ULOQ | 493 (99%) | 243 (99%) | 250 (98%) |
| <LOD/LLOQ | 7 (1%) | 3 (1%) | 4 (2%) |
| Presence of B2M | |||
| ≥LOD/LLOQ, =ULOQ | 499 (100%) | 246 (100%) | 253 (99%) |
| <LOD/LLOQ | 2 (0%) | 0 (0%) | 2 (1%) |
Abbreviations: B2M, beta-2 microglobulin; LOD, lower limit of detection; LLOQ, lower limit of quantification; ULOQ, upper limit of quantification.